Comparative Pharmacology
Head-to-head clinical analysis: REVEX versus ZIMHI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REVEX versus ZIMHI.
REVEX vs ZIMHI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nalmefene is an opioid antagonist that competitively binds to mu, delta, and kappa opioid receptors, reversing or preventing opioid effects.
Opioid receptor antagonist; reverses opioid effects by competitively binding to mu-opioid receptors.
0.5 mg to 1 mg intravenous, intramuscular, or subcutaneous, repeated every 2 to 5 minutes as needed, up to a maximum of 2 mg total dose per episode.
5 mg intramuscularly every 2-3 minutes as needed; maximum 3 doses.
None Documented
None Documented
Terminal elimination half-life: 2.4-4.2 hours in adults; prolonged in renal impairment (up to 50 hours).
Terminal half-life: 2.5-4 hours; clinical context: short duration requires repeat dosing for sustained opioid effects.
Renal: 60% as unchanged drug and metabolites; fecal: 40% via biliary elimination.
Renal: 30-35% unchanged; biliary/fecal: 50-60% as metabolites.
Category C
Category C
Opioid Antagonist
Opioid Antagonist